Clinical trial · Observational
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood: a Multi-center, Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were identified to accurately establish an early diagnosis model for liver cancer and verify its efficacy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Proteomics | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Hepatocellular carcinoma group
- description
- Patients with histologically or cytological, imaging confirmed untreated hepatocellular carcinoma.
- interventionNames
- Diagnostic Test: Proteomics
- label
- Benign liver lesions group
- description
- Untreated patients with confirmed or suspected benign liver lesions by histopathology, or with high suspicion of benign liver lesions by imaging evaluation or other routine clinical diagnosis
- interventionNames
- Diagnostic Test: Proteomics
- label
- Healthy people group
- description
- People without any liver disease
- interventionNames
- Diagnostic Test: Proteomics
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Voluntarily sign informed consent. 2. Male or female, age equal to or greater than 18 years and less than 75 years. 3. Patients with liver cancer who have been diagnosed or suspected for the first time within 42 days prior to blood collection 4. The subject has not undergone any local or systemic anti-tumor therapy before blood collection, including (but not limited to) tumor surgical treatment for any purpose, local or systemic chemoradiotherapy, targeted therapy (including anti-angiogenic drugs), immunotherapy, cancer vaccine and hormone therapy, etc. 5. Patients with histologically or cytological, radiographically confirmed hepatocellular carcinoma. Exclusion Criteria: 1. Female subjects who are pregnant or breastfeeding. 2. Previous organ transplantation or non-autologous bone marrow or stem cell transplantation. 3. Received drugs with anti-tumor effects for other diseases within 30 days before blood collection, such as drugs used for the treatment of immunorheumatic diseases such as methotrexate, cyclophosphamide, thiazoprine, chlorambucil, etc., drugs for the treatment of breast diseases, such as tamoxifen, etc. 4. History of previous malignant tumors. 5. Having other malignant tumors or multiple primary tumors at the same time.
References
Publications (0)
Data not yet available